TrialCurveADMYRE: reconstructed Kaplan–Meier curves
Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Relapsed/Refractory Multiple Myeloma: Results for Patients Aged <75 Years. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Cancers (Basel). 2025 Oct 29;17(21):3482. doi: 10.3390/cancers17213482 |
|---|---|
| DOI | 10.3390/cancers17213482 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival without PD confirmation by Independent Review Committee — Patients aged <75 years
From figure panel A · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: P+DXM 2.5 months; DXM 1.1 months. Survival at 12 months: P+DXM 11%. Hazard ratio P+DXM vs DXM 0.53 (95% CI 0.38–0.73).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| P+DXM | 145 | 112 | 2.5 |
| DXM | 71 | 60 | 1.1 |
- P+DXM vs DXM: reconstructed HR 0.53 (95% CI 0.38–0.73)
Landmark survival (reconstructed)
| Time | P+DXM | DXM |
|---|---|---|
| 6 mo | 21.2% | 4.7% |
| 12 mo | 11.1% | — |
| 18 mo | 6.8% | — |
| 24 mo | 4.5% | — |
Checks against the published figure
- P+DXM median: printed 2.6, reconstructed 2.55 pass
- DXM median: printed 1.1, reconstructed 1.1 pass
- hazard ratio (direction inferred): printed 0.523, reconstructed 0.525 pass
Progression-free survival with PD confirmation by investigator's assessment — Patients aged <75 years
From figure panel B · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: P+DXM 4.5 months; DXM 1.7 months. Survival at 12 months: P+DXM 22%; DXM 12%. Hazard ratio P+DXM vs DXM 0.47 (95% CI 0.33–0.69).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| P+DXM | 145 | 85 | 4.5 |
| DXM | 71 | 46 | 1.7 |
- P+DXM vs DXM: reconstructed HR 0.47 (95% CI 0.33–0.69)
Landmark survival (reconstructed)
| Time | P+DXM | DXM |
|---|---|---|
| 6 mo | 40.7% | 12.2% |
| 12 mo | 21.9% | 12.2% |
| 18 mo | 12.8% | — |
| 24 mo | 9.6% | — |
Checks against the published figure
- P+DXM median: printed 4.5, reconstructed 4.52 pass
- DXM median: printed 1.7, reconstructed 1.7 pass
- hazard ratio (direction inferred): printed 0.468, reconstructed 0.474 pass
Overall survival — All randomized patients aged <75 years
From figure panel · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: P+DXM 13.3 months; DXM 8.5 months. Survival at 18 months: P+DXM 41%; DXM 35%. Hazard ratio P+DXM vs DXM 0.72 (95% CI 0.52–0.99).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| P+DXM | 145 | 99 | 13.3 |
| DXM | 71 | 61 | 8.5 |
- P+DXM vs DXM: reconstructed HR 0.72 (95% CI 0.52–0.99)
Landmark survival (reconstructed)
| Time | P+DXM | DXM |
|---|---|---|
| 6 mo | 70.8% | 62.4% |
| 12 mo | 53.7% | 41.2% |
| 18 mo | 41.1% | 34.9% |
| 24 mo | 33.5% | 20.6% |
| 36 mo | 24.0% | 12.5% |
| 48 mo | 15.0% | 7.8% |
| 60 mo | 7.5% | 3.9% |
Checks against the published figure
- P+DXM median: printed 13, reconstructed 13.3 pass
- DXM median: printed 8.1, reconstructed 8.48 pass
- hazard ratio (direction inferred): printed 0.711, reconstructed 0.719 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- CPT-MM301: Overall survival; Progression-free survival (Independent Assessment Committee)
- CEPHEUS: Overall survival; Progression-free survival
- Mesenchymal stromal cells for steroid-resistant acute GVHD: Cumulative incidence of leukemia relapse; Non-relapse mortality (NRM); Overall survival; c
- CLL12: Event-free survival (EFS); Overall survival (OS)
- Acalabrutinib vs chlorambucil + rituximab in CLL (Asian phase 3): BICR-assessed duration of response; BICR-assessed progression-free survival; Overall survi
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials